Opiant Pharmaceuticals, Inc.
News
Indivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science Portfolio
Benzinga Indivior PLC INVVY INDV has completed the acquisition of Opiant Pharmaceuticals, Inc. OPNT The transaction strengthens Indivior's addiction treatment and science portfolio by adding Opiant's late-stage assets, notably OPNT003, an investigational opioid overdose treatment designed to offer an important treatment option to address the current wave of US opioid overdoses from powerful synthetic opioids, such as fentanyl.\n more…
Opiant Pharmaceuticals (NASDAQ:OPNT) Share Price Passes Above 200 Day Moving Average of $15.60
Ticker Report Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT Get Rating) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $15.60 and traded as high as $21.00. Opiant Pharmaceuticals shares last traded at $20.98, with a volume of 30,200 shares. Wall ...\n more…
Short Interest in Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Expands By 41.7%
Zolmax Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT Get Rating) saw a significant increase in short interest in January. As of January 31st, there was short interest totalling 39,400 shares, an increase of 41.7% from the January 15th total of 27,800 shares. Based on an average trading volume of 113,700 shares...\n more…
Short Interest in Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Grows By 41.7%
Ticker Report Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT Get Rating) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 39,400 shares, a growth of 41.7% from the January 15th total of 27,800 shares. Based on an average...\n more…